Thrombophilia Market Report 2026

The thrombophilia market size has grown strongly in recent years. It will grow from $18.18 billion in 2025 to $19.6 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to rising prevalence of inherited blood disorders, limited awareness of thrombophilia, growth in hospital infrastructure, early adoption of anticoagulant therapies, increasing cardiovascular disease incidences.

The thrombophilia market size is expected to see strong growth in the next few years. It will grow to $26.5 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to expansion of genetic testing services, adoption of AI-based diagnostic tools, integration of telehealth platforms, growth in homecare anticoagulant management, increasing healthcare expenditure in emerging markets. Major trends in the forecast period include personalized anticoagulant therapy, increased genetic screening for thrombophilia, advanced diagnostic testing for blood clotting disorders, rise in awareness programs for blood disorders, integration of telemedicine in thrombophilia management.

The rising prevalence of thrombophilic conditions is expected to drive the growth of the thrombophilia market in the coming years. Thrombophilic diseases, commonly referred to as thrombophilia, are a group of disorders characterized by an increased tendency to develop blood clots (thrombosis). These conditions significantly influence the thrombophilia market, impacting diagnostic methods, treatment options, and ongoing research. For example, in July 2025, PubMed reported that Factor V Leiden and prothrombin G20210A mutations significantly increase the risk of stillbirth, with a pooled odds ratio (OR) of 2.35 and 2.62, respectively. The study also found a positive correlation between thrombophilic mutations and antithrombin deficiency. As such, the growing prevalence of thrombophilic conditions is driving the market for thrombophilia treatments.

Key companies in the thrombophilia market are increasingly focusing on developing innovative therapies, such as long-acting fusion protein therapies for coagulation factor replacement, to address the growing demand for better treatment durability, fewer administrations, and enhanced patient compliance. These long-acting therapies combine coagulation factors with carrier proteins or Fc fragments to extend their half-life in the bloodstream, reduce the frequency of dosing compared to traditional treatments, and improve overall patient quality of life. For instance, in May 2023, researchers at the University of California, San Diego, introduced Eloctate, a groundbreaking technology that enhances the stability and half-life of coagulation factors. By combining this technology with existing therapies, they aim to create long-acting treatments that require less frequent administration, improving patient adherence and quality of life.

In March 2025, Tempus AI, a US-based provider of AI-driven precision medicine and oncology diagnostics, acquired Ambry Genetics for an undisclosed amount. This acquisition is intended to expand Tempus' genetic diagnostics portfolio and integrate Ambry’s expertise in hereditary testing, including diagnostics for inherited conditions like thrombophilia, as well as cardiology, neurology, and rare diseases.

Major companies operating in the thrombophilia market are Pfizer Inc., F. Hoffmann-La Roche Limited, Fresenius Kabi AG, Hikma Pharmaceuticals PLC., Novartis AG, Shenzhen Hepalink Pharmaceutical Group Co. Limited, Teva Pharmaceutical Industries Limited, Sanofi SA, Boehringer Ingelheim GmbH, Instrumentation Laboratory SpA, Johnson & Johnson, Bristol-Myers Squibb, Roche, Abbott, C. H. Boehringer Sohn, Portola Pharmaceuticals, Daiichi Sankyo, Bayer Group, CSL Behring, Merck & Co Inc., Janssen Pharmaceuticals.

North America was the largest region in the thrombophilia market in 2025. The regions covered in the thrombophilia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the thrombophilia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the thrombophilia market by increasing the cost of imported diagnostic equipment, anticoagulant drugs, and laboratory reagents, particularly affecting segments such as genetic testing and anticoagulant therapy. Regions like Europe and North America, which rely on imports from Asia-Pacific, are most impacted. While tariffs have increased costs, they have also incentivized local production and innovation, enabling domestic manufacturers to expand and optimize thrombophilia solutions for local markets.

The thrombophilia market research report is one of a series of new reports that provides thrombophilia market statistics, including thrombophilia industry global market size, regional shares, competitors with a thrombophilia market share, detailed thrombophilia market segments, market trends and opportunities, and any further data you may need to thrive in the thrombophilia industry. This thrombophilia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Thrombophilia is a blood disorder that increases the likelihood of blood clotting in the veins and arteries, which can lead to severe complications such as heart attack, stroke, kidney failure, and pulmonary embolism. This condition can be caused by blood clotting in the arteries and veins or by an inherited (genetic) or acquired disposition.

The primary types of thrombophilia include Factor V Leiden, prothrombin 20210, antiphospholipid syndrome, and other related conditions. Factor V Leiden refers to a mutation in one of the blood-clotting factors. Common drugs used to treat thrombophilia include Heparin, Warfarin, and other anticoagulants, which are administered through various routes, such as oral and parenteral (injection). The key end-users of thrombophilia treatments include hospitals, home health agencies, specialty centers, and other healthcare facilities.

The thrombophilia market consists of sales of rivaroxaban, apixaban, and thrombolytics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.